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Abstract
Background: To assess the accuracy of findings from the clinical history, symptoms, signs and
diagnostic tests (ECG, CXR and natriuretic peptides) in relation to the diagnosis of left ventricular
systolic dysfunction (LVSD) in a primary care setting.
Methods: Diagnostic accuracy systematic review, we searched Medline (1966 to March 2008),
EMBASE (1988 to March 2008), Central, Cochrane and ZETOC using a diagnostic accuracy search
filter. We included cross-sectional or cohort studies that assess the diagnostic utility of clinical
history, symptoms, signs and diagnostic tests, against a reference standard of echocardiography.
We calculated pooled positive and negative likelihood ratios and assessed heterogeneity using the
I2 index.
Results: 24 studies incorporating 10,710 patients were included. The median prevalence of LVSD
was 29.9% (inter-quartile range 14% to 37%). No item from the clinical history or symptoms
provided sufficient diagnostic information to "rule in" or "rule out" LVSD. Displaced apex beat
shows a convincing diagnostic effect with a pooled positive likelihood ratio of 16.0 (8.2–30.9) but
this finding occurs infrequently in patients. ECG was the most widely studied diagnostic test, the
negative likelihood ratio ranging from 0.06 to 0.6. Natriuretic peptide results were strongly
heterogeneous, with negative likelihood ratios ranging from 0.02 to 0.80.
Conclusion: Findings from the clinical history and examination are insufficient to "rule in" or "rule
out" a diagnosis of LVSD in primary care settings. BNP and ECG measurement appear to have
similar diagnostic utility and are most useful in "ruling out" LVSD with a normal test result when
the probability of LVSD is in the intermediate range.
Background
Left Ventricular Systolic Dysfunction (LVSD) is a major
clinical problem worldwide. In the UK alone it has been
estimated that 878,000 people have definite or probable
LVSD, with 63,000 new cases annually [1]. A diagnosis of
LVSD carries a poor prognosis with 40% of patients dying
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within a year of first diagnosis. People living with LVSD
report a significantly lower quality of life than the general
population. The annual cost to the National Health Serv-
ice attributable to LVSD has been estimated at around
£625 million [1].
The European Society of Cardiology (ESC) state that there
is no exclusive definition of Heart Failure although it is
recognised as a syndrome in which abnormal cardiac
function is a cause for the heart being unable to pump
blood at the rate required to meet the needs of the metab-
olizing tissues [2]. LVSD is one possible reason for heat
failure characterised by compromised ventricular function
leading to a variety of symptoms such as fatigue, breath-
lessness, and oedema. The ESC has proposed that the
diagnosis of LVSD depends on the presence of some or all
of these symptoms along with objective evidence of car-
diac dysfunction at rest [2]. Accurate diagnosis of LVSD
with echocardiography is important for two reasons:
firstly to determine the underlying cause of heart failure-
broadly LVSD, valve disease, or diastolic dysfunction of
the left ventricle (heart failure with preserved systolic
function); and secondly to initiate treatments to alleviate
symptoms, delay progression and improve prognosis [3].
National and international guidelines on the diagnosis
and management of LVSD have been published, [2-4] and
current diagnostic algorithms support a structured path-
way of history, examination, and diagnostic testing with
brain natriuretic peptide (BNP) and electrocardiogram
(ECG) as part of the initial diagnostic assessment by fam-
ily physicians (GPs) [3]. As access to echocardiography
services is limited by the availability of equipment and
appropriately trained personnel, this approach is likely to
remain the most cost effective way of diagnosing LVSD in
the community [5].
Previous reviews have sought to assess the diagnostic test
accuracy of BNP or ECG measurement in primary care or
the accident and emergency environments [6-14]. How-
ever, these studies assessed BNP and ECG testing in isola-
tion; not in the context of initial presentation (symptom
and signs) and the incremental diagnostic value of BNP or
ECG measurement for risk-stratifying patients in terms of
onward referral for echocardiography.
The aim of this systematic review and meta-analysis is to
identify diagnostic accuracy studies based in primary care
that evaluate both individual symptoms and signs, BNP
and ECG measurement in patients presenting with sus-
pected LVSD, as a means of evaluating and quantifying
diagnostic algorithms for suspected LVSD in primary care.
Methods
We followed the recommended methods of the Cochrane
Diagnostic Accuracy Group for systematic reviews of Diag-
nostic tests [15]. A search strategy was devised taking into
account existing filters that identify diagnostic accuracy
studies (Additional file 1) [16]. The following were
searched: MEDLINE (1966 to March 2008), EMBASE
(1988 to March 2008), CENTRAL, and ZETOC (confer-
ence proceedings). Additionally, AR searched the bibliog-
raphies of all relevant retrieved papers. No restrictions
were placed on language of publication or publication sta-
tus.
Study Selection
Inclusion criteria were as follows:
• Population: study participants must have been recruited
from a community or primary care setting and have symp-
toms suggestive of LVSD. Screening studies in asympto-
matic patients were excluded as were case control studies
in which control patients were compared with patients
with previously established LVSD.
￿ Study design and reference standard: studies should
assess diagnostic accuracy by means of cross sectional
study and application of echocardiography as the refer-
ence standard test.
￿ Index tests: studies must assess the value of symptoms,
signs, ECG, Chest X ray (CXR) and/or natriuretic peptides
in diagnosing LVSD.
￿ Outcome measures: studies must report data that will
allow 2 × 2 table construction for the assessment of diag-
nostic accuracy for individual symptoms, signs or diag-
nostic tests.
Three reviewers (VM, AR, and GF) independently
reviewed the titles and/or abstracts of retrieved citations.
The full text of potentially relevant studies were retrieved
and reviewed. Disagreements were resolved by consensus
or by consultation with a fourth reviewer (TF). We inde-
pendently assessed the quality of each study and extracted
data to construct a 2 × 2 table for each symptom, sign or
diagnostic test.
Assessment of Study Quality
The QUADAS quality assessment tool was modified
alongside a quality assessment tool for clinical prediction
rules to produce a seven-point quality assessment score
for each included study [17,18]. Any disagreement on
study quality was resolved by consensus with a third
reviewer (TF).BMC Family Practice 2008, 9:56 http://www.biomedcentral.com/1471-2296/9/56
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Data Extraction
Two independent reviewers extracted data onto a spread-
sheet for the construction of 2 × 2 tables.
Quantitative data synthesis
Meta-DiSc 1.2 software was used to analyse the extracted
data [19]. We calculated positive and negative likelihood
ratios for each study, with random methods used in the
analysis. Heterogeneity was assessed using the I2 index
[20], where I2 ≤ 50% studies were considered to be suffi-
ciently homogeneous to allow pooling and produce a
summary estimate of diagnostic test accuracy. In situa-
tions of significant between-study heterogeneity the range
of positive and negative likelihood ratios are presented
[21].
Results
We identified 15,065 potentially relevant articles. After
scanning titles and abstracts, we retrieved the full text of
70 articles for further evaluation. Twenty-four studies met
our inclusion criteria and were included in the final anal-
ysis (Figure 1) [22-45]. Reasons for exclusion of studies (n
= 46) included, incorrect study design, population derived
from duplicate publication, and population included
patients previously diagnosed with LVSD.
Flow of studies through review process Figure 1
Flow of studies through review process.
Flow of studies through review process  
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Characteristics of studies
All included studies were cross-sectional in design and
were conducted in a primary or ambulatory care setting
(Additional file 2). Of the 10,710 patients with symptoms
or signs of LVSD, the median prevalence of LVSD was
29.9% (inter-quartile range 14% to 37%). One study also
included patients considered to be at high risk of LVSD on
the basis of previous clinical history [42]. None of the
studies included patients with previous echocardio-
graphic diagnosis of LVSD. Of the included studies, five
assessed the diagnostic usefulness of various symptoms
and signs, ten assessed ECGs and fourteen assessed one or
more of the natriuretic peptides.
Quality of included studies
The overall quality of included studies is summarized in
Additional file 3. Adequate description and inclusion of
important predictors (symptoms, signs and diagnostic
tests) occurred in half of the included studies. Similarly
absence of blinding between index test (symptom, sign or
diagnostic test) and reference standard test occurred in
half of the included studies.
Definition of predictors of LVSD
A variety of definitions of ECG abnormality were used. In
two studies, ECGs were interpreted by GPs, and in the
remaining studies interpretation was by secondary care
physicians. Four studies did not explicitly describe criteria
for deciding whether an ECG was abnormal. The remain-
der used a variable number of features such as evidence of
previous MI, left ventricular hypertrophy and bundle
branch block. One of the studies assessing chest x ray used
only a cardiothoracic ratio greater than 0.5 as an indicator
of abnormality. The other study used the presence of
either pulmonary oedema or cardiomegaly, neither of
which was objectively quantified. The cut-off points for
natriuretic peptides had wide variability, and were chosen
for differing reasons. In some studies the test manufac-
turer's recommended cut-off was used, and in others it
was chosen to give optimum test performance in their
study. BNP cut-offs varied from 10 pg/mL (2.89 pmol/L)
to 100 pg/mL (28.9 pmol/L) (median 38.51 pg/mL
(11.13 pmol/L)). Where studies reported results for more
than one cut-off point, we included only the cut-off clos-
est to the median. NTproBNP cut-offs ranged from 92.77
pg/mL (10.97 pmol/L) to 449.07 pg/mL (53.1 pmol/L)
(median 146.73 pg/mL (17.35 pmol/L)). Where multiple
cut points were reported we used only the cut-off closest
to the median. The two studies assessing NTproANP chose
cut-offs of 537.6 pmol/L and 0.8 nmol/L.
Definition of reference standard test
All studies used a reference standard of echocardiography.
In four studies the Echocardiogram was assessed on a
purely qualitative basis. Four other studies used the Euro-
pean Society of Cardiology (ESC) guidelines for LVSD,
which combine symptoms of LVSD with objective evi-
dence of cardiac dysfunction at rest [2]. The most com-
monly reported quantitative measurement of cardiac
function was ejection fraction. Twelve studies explicitly
used ejection fraction as a measure of cardiac function
with cut-offs ranging from 35% to 50% (median 40%).
The ESC guidelines suggest that an ejection fraction <
40%, implies abnormal systolic function [2].
Diagnostic value of symptoms, signs and diagnostic tests
The diagnostic value from the clinical history (four items),
symptom (four items), clinical signs (five items) and
available diagnostic tests are summarized in Additional
file 4. No item from the clinical history or symptoms pro-
vided sufficient diagnostic information to rule in or rule
out LVSD. Of the clinical signs assessed, displaced apex
beat shows a convincing diagnostic effect with a pooled
positive likelihood ratio of 16.0 (8.2–30.9), but this was
based on findings from only two studies. The presence of
a third heart sound shows a wide range of positive likeli-
hood ratios (1.6 to 32.4) as does the presence of a raised
jugular venous pulse (2.7 to 7.4) The range of positive
likelihood ratios for peripheral oedema (0.96 to 1.48)
suggests that this is an uninformative clinical sign (Addi-
tional file 4)
In terms of diagnostic tests, chest radiography appears to
be uninformative with positive likelihood ratios in two
studies being 1.2 and 1.7. ECG was the most widely stud-
ied diagnostic test, the negative likelihood ratio ranging
from 0.06 to 0.76 (Additional file 4). Two studies did
report on the combination of ECG and a positive history
of myocardial infarction with a pooled positive likelihood
ratio of 2.8.
Not unexpectedly, given the wide variation in diagnostic
threshold, BNP results were strongly heterogeneous, with
negative likelihood ratios ranging from 0.02 to 0.80. Sim-
ilarly, NTproANP and NTproBNP both had high heteroge-
neity with a broad range of reported negative likelihood
ratios (Additional file 4).
Discussion
This diagnostic accuracy systematic review of LVSD shows
that the diagnostic value of single items from the clinical
history or symptoms in patients presenting to their family
practitioner is modest. Likelihood ratios for some clinical
signs-raised JVP, displaced apex beat and third heart
sound, appear to be more diagnostically useful in ruling
in LVSD but are based on a small number of studies in
which the prevalence of these clinical signs is low. It is
likely these florid clinical signs occur in patients for whom
there is little diagnostic uncertainty concerning LVSD
compared to the more typical range of patients whoseBMC Family Practice 2008, 9:56 http://www.biomedcentral.com/1471-2296/9/56
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diagnosis needs to be established in routine clinical prac-
tice in primary care. Patients with a history of prior MI are
likely to be a more diagnostically useful group in terms of
probability of LVSD (Additional file 4). These findings
highlight the challenges of evaluating the diagnostic util-
ity of items from clinical history and examination in pri-
mary care. "Ruling in" or "ruling out" a diagnosis of LVSD
on clinical grounds is not likely to be possible. Insufficient
evidence exists to determine whether combinations of
signs and symptoms are more diagnostically useful.
Addition of near patient diagnostic tests does have value
in terms of "ruling out" the probability of LVSD. ECG and
BNP testing both appear to provide important diagnostic
information when they are negative in "ruling out" the
presence of LVSD. The nomogram in Figure 2 quantifies
the importance of these diagnostic tests in the context of
the prior probability/prevalence of LVSD. In situations
where the prior prevalence of LVSD is 30%, a figure that
matches the median prevalence in the included studies in
this diagnostic accuracy review, a negative ECG or BNP
lowers the post-test probability of LVSD to 10%. In these
situations, pursuit of alternative diagnosis or a watchful
waiting (rather than referral) strategy would seem to be a
cost effective and clinically appropriate approach [46].
The results of this review are consistent with previously
published research in relation to diagnostic testing for
LVSD in terms of BNP measurement [10-12,14]. This
review shows that the diagnostic value of ECG measure-
ment appears to be equivalent to BNP – most useful as a
"ruling out" test in situations of low to intermediate pre-
test probability (Figure 2). Furthermore, including the
diagnostic values of clinical history findings, symptoms
and signs more accurately reflects the diagnostic approach
of clinical practice, where the probability of the target dis-
order – in this case LVSD – is revised with additional
information from the clinical history, along with the pres-
ence or absence of symptoms and signs in an individual
patient [47].
Normogram showing diagnostic utility Figure 2
Normogram showing diagnostic utility.
Normogram showing the diagnostic utility of a negative ECG or BNP result  
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The significant heterogeneity between many of the
included studies is not unusual in terms of diagnostic
accuracy systematic reviews [47], reflecting differences in
the definitions used in the reference standard echocardio-
grams in relation to LVSD, different cut-points for natriu-
retic peptide measurement and differences in the
definition of "abnormal" ECG findings (Additional file
2). Despite these shortcomings, a consistent finding is
that the likelihood ratios for individual features from the
clinical history and examination are modest, and are not
likely to produce definitive revisions in the probability of
LVSD alone. The findings from this systematic review also
support the sequential diagnostic algorithm recom-
mended in clinical guidelines for heart failure [4,48]. Our
findings would also support a more quantified approach
to the diagnosis of LVSD, which could be incorporated
into a computer-based clinical decision support system
[49].
Future studies will need to address the incremental value
of combined findings from the clinical history and exam-
ination. The relative value of BNP or ECG measurement is
likely to relate to issues of experience and training of fam-
ily doctors in ECG interpretation, which can be variable
[5,50]. Future studies should also incorporate cost effec-
tiveness data in relation to alternative diagnostic testing,
particularly in relation to determining other structural
abnormalities such as valvular disease and left ventricular
hypertrophy [51]. Lastly, as evidence accumulates in rela-
tion to the strong prognostic role of natriuretic peptides in
patients with heart failure [52,53], questions about the
definition and value of the diagnostic label of heart failure
has arisen using echocardiography as a reference standard
[54]. However, the randomised trial evidence for thera-
peutic interventions are based on studies that use echocar-
diographic left ventricular ejection fraction as an entry
criteria [55]. Future diagnostic accuracy studies may wish
to consider use of supplementary or alternative reference
standards in conjunction with echocardiography and fol-
low up patients to assess their longer term outcome [53].
Conclusion
In conclusion, this diagnostic accuracy systematic review
shows that findings from the clinical history and examina-
tion are insufficient to "rule in" or "rule out" a diagnosis
of LVSD. BNP and ECG measurement appear to have sim-
ilar diagnostic utility and are most useful in "ruling out"
LVSD with a normal test result when the probability of
LVSD is in the intermediate range. Future studies should
assess the combined value of clinical findings and diag-
nostic testing in primary care.
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